Based on these promising preclinical results, a phase I (first-in-man) clinical trial in patients with spinal cord injury was conducted, proving excellent safety and tolerability of a human anti-Nogo-A antibody. With the support of the Regenerative Medicine Technologies Platform of Wyss Zurich, the team will now produce a new batch of this therapeutic anti-Nogo-A antibody. This antibody will enable the critical transition to phase II clinical trials, aimed to determine clinical efficacy of the anti-Nogo-A antibody in patients with spinal cord injury.
Beyond the field of spinal cord injury, these clinical studies will serve as a model for other disorders where nerve fibers of the central nervous system become injured, and may thus have a broad impact for the treatment of neurological diseases in general. A positive outcome of the planned clinical trials would be a real breakthrough in neurology, neuroscience and the field of tissue regeneration and repair.
Download CeNeReg factsheet
Watch a related video produced by the Swiss Television (SRF) in 2014: Hoffnung für Gelähmte (in German)
FUNDING PARTNERS
Co-funded by the Horizon 2020 Framework Programme of the European Union
European Research Council
Swiss National Science Foundation
Christopher & Dana Reeve Foundation